Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses clinical trial endpoints and individualizing treatment in patients with ovarian cancer.
Clinical Pearls
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses clinical trial endpoints and individualizing treatment in patients with ovarian cancer.
The last approved agent in advanced epithelial ovarian cancer was the carboplatin + gemcitabine doublet used in platinum-sensitive recurrence
This doublet was approved based on a PFS endpoint
Since then, it has been difficult to get ovarian cancer drugs approved based on a PFS endpoint
The challenge remains to see the value of PFS
Maintaining long term tumor control, though of value to the patient, may not be of value to regulators
Though certain agents may be equally efficacious, they may have different toxicity profiles
Ideally, clinicians need agents approved on a PFS endpoint in order to individualize treatments
